BrainTale, a Strasbourg, France-based medtech company focused on improving brain care, raised €4.5M in funding.
The round was led by Capital Grand Est and MACSF.
The company intends to use the funds to accelerate its expansion in Europe and the United States.
Co-founded by Professors Louis Puybasset (Intensivist, Paris Region Greater Hospitals, Paris), Damien Galanaud (Neuroradiologist, Paris Region Greater Hospitals, Paris), Lionel Velly (Intensivist, Hôpital de la Timone, Marseille Hospitals, Marseille), Didier Cassereau (Research Professor, ESPCI), Vincent Perlbarg (Engineer and PhD in Medical Physics), and LallianSe, BrainTale is a medtech company deciphering white matter to enable brain care with clinically validated prognostic solutions. With non-invasive, sensitive and reliable measurements of white matter microstructure alterations, the company offers a digital biomarkers platform to support clinical decision-making. BrainTale enables the identification of patients at risk, early diagnosis and monitoring of disease progression and the effectiveness of treatments in neurology, in particular for demyelinating diseases, amyotrophic lateral sclerosis and neurodegenerative diseases.
Since its inception in 2018, the company has implemented a comprehensive quality management system and is now ISO 13485:2016 certified, with a suite of products available on the European market under the European Medical Device Regulation (MDR).
Customers include hospitals (Paris Region Greater Hospitals, Hôpitaux Universitaires de Strasbourg) and biotech (Minoryx), as well as partners in the United States (Massachusetts General Hospital – Harvard).
FinSMEs
20/06/2023